Artificial intelligence and machine learning (AI/ML) in the biopharmaceutical industry have been a hot topic for years already, with a host of start-up companies popping up and most of the large drug makers either partnering with them or acquiring them.
AI Starts To Make Its Mark In Pharma Marketing
The early adoption of artificial intelligence/machine learning has centered around drug discovery, but the technologies are being applied to other fields, including pharma marketing.
More from Innovation
• By
Bringing AI and digital healthtech innovation to patients works most efficiently via a three-way partnership in which clinicians and cloud services have equal weighting with a powerhouse innovator, Royal Philips told In Vivo during ECR 2025.
• By
In Vivo spoke with Tran Le and Sohit Gatiganti, co-founders of Grove AI and developers of Grace, a voice-based AI agent to streamline clinical trial processes.
• By
The Barcelona Health Hub is a nonprofit that seeks to advance digital health innovation by bringing together start-ups, investors, health care institutions and corporations.
• By
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.
More from Business Strategy
• By
In Vivo looks at the top partnerships and investments in AI-driven companies in 2024. Collaborations and investments spanned multiple therapeutic areas, with a particular focus on small molecule discovery, protein degradation and neurological diseases.
• By
The biotech industry faces a surge in litigation due to stricter regulations and patent disputes. This legal storm challenges companies and investors, but there are proactive strategies for mitigating risk in this dynamic landscape.
• By
In September last year, J&J lost a court case surrounding its 2019 purchase of Auris health, and was ordered to pay over $1bn in damages. Reactions to the potentially precedent-setting news were harsh and quick. In Vivo spoke to legal, M&A and BD experts from across the medtech industry to learn more about the true impacts.